In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical response to dupilumab can be differentiated on a molecular basis.

Dupilumab was safe and effective in treating a group of six children and young adults with inborn errors of immunity and moderate to severe atopic dermatitis, according to a study published in ...

DeepCure designed DC-15442 to meet the demand for an oral alternative that is not only equally effective as dupilumab, but also has excellent safety, given that many patients are children and ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

The NIH has awarded Emma Guttman-Yassky, MD, PhD, a $6.6 million grant to investigate dupilumab as a treatment for children with alopecia areata, Mount Sinai announced in a press release. &ldquo ...